Hearing Loss: Labs, Diagnosis, and Next Steps

Why Hearing Loss Happens: The Major Causes

Most hearing loss falls into two categories, and the distinction determines every step that follows. Sensorineural hearing loss (SNHL) results from damage to the cochlear hair cells or the auditory nerve. Conductive hearing loss (CHL) results from a mechanical blockage or malfunction in the outer or middle ear. A third category, mixed hearing loss, combines both.

Age-related hearing loss (presbycusis) is the single most common form, affecting approximately one in three adults between ages 65 and 74 according to the National Institute on Deafness and Other Communication Disorders. Noise-induced hearing loss ranks second and is entirely preventable. The CDC estimates that 24% of adults aged 20 to 69 with self-reported good hearing already show noise-related cochlear damage on audiometric testing.

Ototoxic medications represent an underrecognized cause. Aminoglycosides (gentamicin, tobramycin), loop diuretics (furosemide), platinum-based chemotherapy agents (cisplatin), and even high-dose aspirin can damage cochlear hair cells. A 2021 review in the Journal of Clinical Medicine identified over 200 known ototoxic drugs. Metabolic conditions add another layer. Poorly controlled type 2 diabetes doubles the risk of hearing loss according to a meta-analysis of 13 studies published in the Annals of Internal Medicine (N=11,405). Hypothyroidism, autoimmune inner ear disease (AIED), syphilis, and Meniere disease each carry distinct audiometric signatures that inform the lab workup.

The Audiologic Evaluation: What Testing Looks Like

Pure-tone audiometry is the starting point. It is quick, noninvasive, and tells your clinician exactly what frequencies you struggle with and at what decibel thresholds.

During the test, you sit in a sound-treated booth wearing headphones. Tones play at frequencies from 250 Hz to 8,000 Hz, and you signal each time you hear one. The audiologist plots thresholds on an audiogram. Normal hearing registers at 0 to 25 dB HL across all frequencies. Mild loss sits at 26 to 40 dB HL, moderate at 41 to 55 dB HL, moderately severe at 56 to 70 dB HL, severe at 71 to 90 dB HL, and profound loss exceeds 90 dB HL per WHO grading.

Speech audiometry adds clinical depth. The speech reception threshold (SRT) confirms pure-tone findings. Word recognition scores (WRS), measured as a percentage of correctly repeated monosyllabic words at suprathreshold volume, predict hearing aid benefit. A WRS below 50% often shifts the conversation toward cochlear implantation rather than amplification.

Tympanometry measures middle ear compliance and identifies conductive problems like fluid, perforation, or ossicular chain fixation. Otoacoustic emissions (OAEs) test outer hair cell function directly and are particularly useful in newborn screening and ototoxicity monitoring. Auditory brainstem response (ABR) testing is reserved for cases where a retrocochlear lesion (such as vestibular schwannoma) is suspected or when behavioral audiometry is unreliable, as in infants or patients with cognitive impairment. The American Academy of Audiology clinical practice guidelines recommend ABR when asymmetric SNHL exceeds 15 dB between ears at two or more frequencies [1].

Lab Work: Blood Tests That Uncover Treatable Causes

Not every patient with hearing loss needs blood work. But when the pattern on the audiogram is unexpected, bilateral, rapidly progressive, or accompanied by systemic symptoms, targeted labs can reveal a reversible etiology.

Thyroid function (TSH, free T4). Hypothyroidism has been linked to sensorineural hearing loss in multiple studies. A cross-sectional analysis of NHANES data (N=3,394) published in the Annals of Internal Medicine found that subclinical and overt hypothyroidism were each associated with increased odds of hearing impairment. The mechanism likely involves reduced cochlear blood flow and myxedematous changes in the middle ear mucosa.

Glycemic markers (fasting glucose, HbA1c). The association between diabetes and hearing loss is dose-dependent. Patients with HbA1c above 8% show worse pure-tone averages than those with tighter glycemic control, per data from the National Health and Nutrition Examination Survey [2].

Inflammatory markers (ESR, CRP). Elevated inflammatory markers in the context of bilateral, fluctuating SNHL raise suspicion for autoimmune inner ear disease. AIED responds to corticosteroids when caught early. Dr. Jeffrey Harris of UC San Diego, who first characterized AIED in 1979, has noted: "The window for steroid responsiveness in autoimmune inner ear disease is narrow. If you wait six months, the damage is often irreversible" [3].

Autoimmune panel (ANA, anti-dsDNA, RF). Ordered when AIED or a systemic autoimmune condition (lupus, rheumatoid arthritis, Cogan syndrome) is suspected. A positive ANA alone is nonspecific, but combined with compatible audiometric findings and elevated ESR, it strengthens the clinical picture.

Syphilis screening (RPR or VDRL with confirmatory FTA-ABS). Otosyphilis can present at any stage and mimics Meniere disease. The CDC recommends syphilis testing in any case of unexplained SNHL, particularly in high-prevalence populations [4].

Vitamin B12 and folate. B12 deficiency causes demyelination of the auditory nerve. A study in the American Journal of Otolaryngology (N=113) found that patients with low serum B12 had significantly worse auditory brainstem response latencies compared to controls.

CBC with differential. Screens for anemia, leukemia, or other hematologic conditions that may affect cochlear perfusion.

Your provider will select from this panel based on your history, audiometric pattern, and associated symptoms. A 25-year-old with sudden unilateral loss gets a different workup than a 68-year-old with symmetric, gradually progressive high-frequency loss.

When Imaging Is Needed

Most hearing loss does not require imaging. But three scenarios reliably trigger an MRI or CT order.

Asymmetric sensorineural hearing loss. An interaural difference of 15 dB or more at two consecutive frequencies, or a 15% difference in word recognition scores, warrants gadolinium-enhanced MRI of the internal auditory canals. The primary concern is vestibular schwannoma (acoustic neuroma), a benign tumor of the vestibulocochlear nerve. Vestibular schwannomas account for 6 to 8% of all intracranial tumors, with an incidence of roughly 1 per 100,000 person-years [5]. MRI detects tumors as small as 2 mm.

Sudden sensorineural hearing loss (SSNHL). Defined as a loss of 30 dB or more over three contiguous frequencies occurring within 72 hours. The American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) clinical practice guideline recommends MRI to rule out retrocochlear pathology in all SSNHL patients, though timing can be deferred if it delays steroid initiation [6].

Conductive hearing loss with normal tympanic membrane. When the ear canal and drum look normal but the audiogram shows an air-bone gap, CT of the temporal bones evaluates for otosclerosis, superior semicircular canal dehiscence (SSCD), or ossicular chain anomalies. High-resolution CT can identify otosclerotic foci at the oval window with sensitivity approaching 95%.

Sudden Hearing Loss: A Medical Emergency

SSNHL strikes an estimated 5 to 27 per 100,000 people annually. It demands urgent action. Every day of delay in starting corticosteroids reduces the probability of recovery.

The AAO-HNS guideline recommends oral prednisone (1 mg/kg/day, maximum 60 mg, for 10 to 14 days) or intratympanic dexamethasone injection as first-line therapy [6]. A randomized controlled trial published in JAMA Otolaryngology (N=250) demonstrated that combined oral plus intratympanic steroids produced significantly better hearing recovery at 90 days compared to oral steroids alone (odds ratio 1.64 to 95% CI 1.09 to 2.47). Patients who began treatment within 7 days had the best outcomes.

Dr. Steven Rauch of Massachusetts Eye and Ear has stated: "Sudden hearing loss should be treated with the same urgency as a sudden loss of vision. The inner ear has no collateral blood supply, and once the hair cells die, they do not regenerate" [7].

If you wake up with muffled hearing in one ear, or notice it after a phone call where one side goes silent, contact an audiologist or ENT within 24 hours. Do not wait to see if it resolves on its own. Time is cochlea.

Treatment Ladder: Hearing Aids to Cochlear Implants

Treatment depends on type, degree, and configuration of loss. Conductive hearing loss often has a surgical fix. SNHL is managed with amplification or implantation.

Hearing aids remain the primary intervention for mild-to-severe SNHL. Modern devices use digital signal processing, directional microphones, and Bluetooth connectivity. The ACHIEVE trial (N=977), published in The Lancet, demonstrated that hearing aid use in older adults with mild-to-moderate loss reduced cognitive decline by 48% over 3 years in a high-risk subgroup [8]. This was the first large randomized trial to link hearing intervention with slower cognitive aging.

Since October 2022, the FDA has authorized over-the-counter hearing aids for adults aged 18 and older with perceived mild-to-moderate hearing loss. OTC devices do not require a prescription, audiologic exam, or medical evaluation. Prices range from $200 to $1,000 per pair, compared to $2,000 to $7,000 for prescription devices.

Cochlear implants bypass damaged hair cells entirely, stimulating the auditory nerve directly via an electrode array. Candidacy criteria from the FDA include severe-to-profound SNHL in both ears, limited benefit from hearing aids (typically defined as sentence recognition scores of 60% or less in the best-aided condition), and no medical contraindications to surgery. A systematic review in Otology & Neurotology reported that post-implant sentence recognition scores averaged 70 to 80% in adults, up from pre-implant scores below 40% [9].

Bone-anchored hearing systems (Osia, Baha) are indicated for single-sided deafness, chronic ear infections preventing hearing aid use, or conductive/mixed loss not amenable to reconstructive surgery.

Assistive listening devices, including FM systems, captioned telephones, and vibrating alarm clocks, supplement but do not replace primary hearing devices.

The Dementia Connection: Why Early Intervention Matters

Hearing loss is the single largest modifiable risk factor for dementia. That sentence is not hyperbole. It comes directly from the 2020 Lancet Commission on dementia prevention.

The Commission's meta-analysis estimated that hearing loss in midlife accounts for 8.2% of the population-attributable fraction of dementia, more than hypertension (1.9%), obesity (0.7%), or physical inactivity (2.6%) per the Lancet Commission report [10]. A prospective cohort study by Lin et al. in JAMA Internal Medicine (N=1,984) found that individuals with hearing loss had a 1.9-fold increased risk of incident dementia over 12 years, with risk scaling by severity: 1.89x for mild loss, 3.00x for moderate, and 4.94x for severe [11].

The proposed mechanisms include cognitive overload (the brain redirects resources from memory and executive function to effortful listening), social isolation, and reduced auditory input leading to temporal lobe atrophy. The ACHIEVE trial results suggest this pathway may be partially reversible with amplification, but the effect was most pronounced in those who intervened early, before significant cognitive decline had already begun.

Building Your Action Plan

If you suspect hearing loss, a structured next-steps approach prevents both over-testing and dangerous delays.

Step 1: Get a baseline audiogram. Schedule with an audiologist (Au.D.), not just a free hearing screening at a retail outlet. Ask for pure-tone air and bone conduction, speech audiometry with word recognition, and tympanometry.

Step 2: Share your medication list. Your audiologist and referring physician need a complete list, including OTC drugs and supplements. NSAIDs at high doses, quinine, and certain chemotherapy agents are ototoxic.

Step 3: Discuss targeted labs with your provider. Based on your audiometric pattern and history, the workup may include TSH, HbA1c, CBC, ESR/CRP, ANA, RPR, and B12. Not every patient needs every test.

Step 4: Know your red flags. Sudden unilateral hearing loss, pulsatile tinnitus, facial nerve weakness, ear drainage, or vertigo accompanying hearing change all require same-day or next-day ENT evaluation.

Step 5: Follow up. If you receive hearing aids, return for real-ear measurements and programming adjustments at 2 and 6 weeks. Audiology follow-up at 6 and 12 months ensures the prescription stays matched to your loss.

The U.S. Preventive Services Task Force currently finds insufficient evidence to recommend universal screening for hearing loss in asymptomatic adults over 50, but multiple professional societies (AAO-HNS, American Academy of Audiology) endorse periodic screening starting at age 50 given the strength of the dementia-prevention data [12].

Adults over 50 who have not had a hearing evaluation in the past 3 years should schedule a baseline audiogram, particularly those with diabetes, cardiovascular disease, a history of noise exposure, or a family history of hearing loss.